A research team from the Department of Pharmacology and Pharmacy at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has found that long-acting injectable (LAI) antipsychotics provide better treatment outcomes than oral antipsychotic medications for patients 65 and older with schizophrenia.
Long-acting Injectable Antipsychotics Show Superior Efficacy in Older Schizophrenia Patients
A research team from the University of Hong Kong has discovered that long-acting injectable antipsychotics are more effective than oral medications for treating schizophrenia in patients aged 65 and older. This finding could influence treatment protocols in Iran, particularly for its aging population with mental health issues. Improved mental health care is crucial for the overall well-being of Iranian society.
👥 Key Players
📰 What Happened
Researchers at the University of Hong Kong found that long-acting injectable antipsychotics are more effective than oral medications for treating schizophrenia in patients aged 65 and older. This discovery could lead to changes in treatment practices, especially in countries with aging populations like Iran.
- Long-acting injectable antipsychotics showed superior efficacy in older patients.
- The study focuses on patients aged 65 and older, a demographic that often faces unique challenges in mental health treatment.
💡 Why It Matters
📚 Background
Schizophrenia is a chronic mental health condition that can severely impact daily functioning, especially in older adults. Long-acting injectable antipsychotics offer a potential solution by improving adherence to treatment.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%